胃肠道非处方药市场（2026—2031）
胃肠道非处方药市场规模预计由2026年的488.8亿美元增至2031年的601.9亿美元，预测期复合年增长率为4.25%。北美是当前最大市场，亚太地区增长最快。
市场研究正文
规模、增长、细分、驱动因素与关键问题
当前质量分 100.00，审核状态 accepted。结构化字段已按 RoboInd 内容层级组织。
核心结论
胃肠道非处方药市场规模预计由2026年的488.8亿美元增至2031年的601.9亿美元，预测期复合年增长率为4.25%。北美是当前最大市场，亚太地区增长最快。
市场走势
结构化指标
| 指标 | 年份 | 数值 | 性质 |
|---|---|---|---|
| 复合年增长率 | 2031 | 4.25% | 机构预测 |
| 市场规模 | 2026 | USD 48.88 billion | 机构预测 |
| 市场规模 | 2031 | USD 60.19 billion | 机构预测 |
细分市场份额
市场结构
| 维度 | 细分项 | 年份 | 份额 |
|---|---|---|---|
| distribution_channel | retail pharmacies | 2025 | 49.450% |
| formulation | tablets | 2025 | 38.450% |
| geography | North America | 2025 | 40.440% |
| indication | heartburn and indigestion | 2025 | 32.440% |
| route_of_administration | oral products | 2025 | 89.340% |
关键结论
- distribution_channel 维度中，retail pharmacies 在 2025 年的公开份额为 49.45%。
- formulation 维度中，tablets 在 2025 年的公开份额为 38.45%。
- geography 维度中，North America 在 2025 年的公开份额为 40.44%。
- indication 维度中，heartburn and indigestion 在 2025 年的公开份额为 32.44%。
- route_of_administration 维度中，oral products 在 2025 年的公开份额为 89.34%。
主要参与者
- Bayer AG
- Johnson & Johnson
- Sanofi
- Pfizer Inc.
- Sun Pharmaceutical Industries Limited
增长驱动因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Rising heartburn, constipation, and acute gastrointestinal symptoms | +0.900% | Global | Long term (≥ 4 years) |
| Self-care and pharmacist-led treatment expansion | +0.700% | North America and Europe | Medium term (2-4 years) |
| OTC switches for acid-control therapies | +0.700% | Japan, Asia-Pacific, and North America | Medium term (2-4 years) |
| E-commerce and omnichannel digestive-health availability | +0.600% | Asia-Pacific, with spillover to the Middle East and Africa | Short term (≤ 2 years) |
| Shift toward proactive gut-health solutions | +0.500% | North America and Europe | Medium term (2-4 years) |
| GLP-1-associated gastrointestinal symptom management | +0.500% | Global, concentrated in North America | Short term (≤ 2 years) |
市场制约因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Safety concerns and long-term acid-suppression misuse | -0.500% | Global | Medium term (2-4 years) |
| Diagnostic substitution and delayed referral for alarm symptoms | -0.300% | Global | Long term (≥ 4 years) |
| Regulatory and evidence complexity for probiotic and herbal claims | -0.300% | Europe and North America | Medium term (2-4 years) |
| Retailer private-label and price-led substitution | -0.600% | North America and Europe | Short term (≤ 2 years) |
报告关注的关键问题
What is the projected value of gastrointestinal OTC drugs in 2031?
The category is projected to reach USD 60.19 billion by 2031, from USD 48.88 billion in 2026, at a 4.25% CAGR.
Which gastrointestinal OTC drug class leads sales?
Antacids led drug-class revenue with a 28.67% share in 2025 because they provide accessible and rapid symptom relief.
What is driving growth in OTC treatment for GERD?
GERD is projected to grow at a 6.23% CAGR through 2031, supported by demand for sustained acid control and new OTC access pathways.
Why are GLP-1 therapies relevant to digestive product demand?
Nausea, vomiting, diarrhea, and constipation affected 50%-60% of patients starting GLP-1 receptor agonists in a 2026 review.
Which sales channel is growing fastest for digestive OTC products?
Online pharmacies are forecast to grow at a 4.87% CAGR through 2031 as consumers value convenience, privacy, and recurring delivery.
Which region is growing fastest for gastrointestinal OTC drugs?
Asia-Pacific is forecast to grow at a 6.98% CAGR from 2026 to 2031, supported by digital commerce and expanding pharmacy access.
市场概览
- 增长最快市场：亚太地区
- 最大市场：北美
- 市场集中度：中等
查看来源：Mordor Intelligence